Halozyme dives on US FDA rejection of HyQ; Baxter, ViroPharma studies halted
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics’ stock lost more than half its value in after-hours trading on 1 August, plunging 55%, or $4.71, after the company's partner Baxter revealed it had received a complete response letter (CRL) from the US FDA for HyQ, a combination of immune globulin infusion and recombinant human hyaluronidase (rHuPH20) as a treatment for primary immunodeficiency disorder.